Bio-path Holdings, INC 8-K filings

Bio-Path Holdings announced its first quarter 2024 financial results, highlighting clinical trial advancements and a strengthened balance sheet through recent financings.

Bio-Path Holdings has terminated its previous at-the-market offering and initiated a new offering to sell up to an additional $1.1 million in common stock.

Bio-Path Holdings has successfully raised approximately $1.2 million through a registered direct offering and concurrent private placement.

Bio-Path Holdings has successfully completed the second, higher dose cohort in its Phase 1/1b clinical trial of BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients.

Bio-Path Holdings has announced the expansion of its global patent portfolio with newly issued patents in Mexico, Australia, and Japan, further protecting its DNAbilize technology.

Bio-Path Holdings has entered into an agreement with H.C. Wainwright & Co. to sell up to $2 million of its common stock through an at-the-market offering.

Bio-Path Holdings announced a clinical and operational update for 2024, highlighting progress across multiple clinical programs and plans for regulatory submissions.

Bio-Path Holdings has successfully completed a registered direct offering, selling 75,000 shares of common stock at $3.99 per share, alongside issuing warrants for additional shares.

Bio-Path Holdings has entered into a securities purchase agreement for a registered direct offering, raising $299,250 through the sale of common stock and warrants.

Bio-Path Holdings has received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement, placing its listing status at risk.

Bio-Path Holdings has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Bio-Path Holdings announced its full year 2023 financial results, highlighting progress in its clinical trials and a net loss of $16.1 million.

Bio-Path Holdings has implemented a 1-for-20 reverse stock split to reduce its outstanding shares and maintain its listing on the Nasdaq Capital Market.

Bio-Path Holdings' stockholders have approved a reverse stock split at a ratio of up to 1-for-50.

Bio-Path Holdings has adjourned its special meeting to January 30, 2024, to gather more votes for a proposed reverse stock split.